This emerging area of precision medicine will see integration of advanced imaging technologies and artificial intelligence in order to produce more accurate diagnoses and personalized treatment plans. Valencia, Spain, is home to Quibim, which stands at the helm of this change. The firm designs AI-driven imaging biomarkers that extract actionable insights from medical images, leading to early detection and monitoring of diseases.

Medical imaging is a cornerstone of modern diagnostics, providing critical information about a patient’s internal structures and functions.
However, traditional imaging techniques often rely on qualitative assessments, which can be subjective and may miss subtle changes indicative of disease. 

The increasing volume of imaging data now poses a significant challenge in the prompt and accurate interpretation of imaging findings. Advanced quantitative analysis tools of imaging data can provide precise, reproducible, and highly actionable metrics for timely clinical decision-making.

Quibim overcomes these challenges with AI-powered biomarkers that give a quantitative measure of medical imaging from modalities such as MRI, CT scans, and PET scans. In detail, this provides the fine tissue characteristics about which disease-specific patterns, which may go unnoticed in common analysis, will be detected with these biomarkers. 

Quibim’s solutions span across diverse medical fields ranging from oncology, neurology to musculoskeletal disorders, equipping clinicians with a comprehensive range of tools as well as a researcher.

Read also: PhynX Lab Unveils Cheiron first medicine genAI search platform in Korea

Funding detail

On 28 January 2025, Quibim revealed that it has closed its $50 million Series A financing round successfully.
The round was co-led by Asabys, through its fund Sabadell Asabys II, and Buenavista Equity Partners, through the BHG I fund created in partnership with Columbus Venture Partners. New investors joining the round include UI Investissements and GoHub Ventures. 

The round is joined by existing investors Amadeus Capital Partners, APEX Ventures, Partech, Adara Ventures, Leadwind, and individual investors such as Tony Fadell, Principal at Build Collective and inventor of the iPod, and Dr. Jonathan Milner, founder of Abcam plc. 

Investor Perspectives

Investors were highly confident in Quibim’s vision and technological prowess. Asabys and Buenavista Equity Partners highlighted that the company could revolutionize precision medicine with AI-powered imaging biomarkers. 

UI Investissements and GoHub Ventures focused on the potential of Quibim’s solutions to revolutionize healthcare diagnostics and personalized treatment approaches. Existing investors reiterated their support for the company, pointing out significant progress and bright prospects ahead.

Read also: Nelly Raises $51 Million to Digitalize Medical Practices Across Europe

Strategic Objectives After Funding

With the infusion of $50 million, Quibim will seek to satisfy several strategic objectives:

Expand Product Pipeline: The company plans to expand the range of imaging biomarkers toward other diseases and medical conditions. This expansion requires the development of new AI models as well as enhancing existing ones in order to increase diagnostic accuracy and further clinical utility.

Enhancement of Foundation AI Models: Quibim is going to invest in the further development of its AI algorithms using the latest techniques in machine learning to enhance precision and robustness of its imaging biomarkers. This will also be an endeavor to improve interpretability of the outputs of the AI models for easier integration in clinical workflows.

Acceleration of Global Commercial Growth: The company will further accelerate the development of its commercial presence, focusing particularly in the U.S. market. By partnering with healthcare providers, research institutions, and pharmaceutical companies, it will drive the implementation of Quibim’s technology in both clinical and research environments.

Regulatory Approvals and Compliance: Quibim will seek regulatory approvals in other markets to expand the access of its products. This involves thorough validation studies to prove that the imaging biomarkers are safe and effective in demonstrating compliance with international healthcare standards.

Research and Development Activities: A significant portion of the budget will be allocated to R&D activities that explore novel applications of imaging biomarkers in monitoring treatment response and predicting patient outcomes. The research will also examine the integration of multi-modal data to better describe disease states.

Read also: Sycai Medical raises €3M to Enhance Early Detection of Abdominal Cancers

Quibim’s Impact on Precision Medicine

Quibim’s AI-powered imaging biomarkers can significantly contribute to precision medicine by:

Early disease detection: Through the detection of minor changes in tissue characteristics, biomarkers may enable the early detection of diseases and provide ample time for intervention and thus better patient outcomes.

Personalized treatment planning: The quantitative insights of the biomarkers allow clinicians to tailor the treatment plans based on the specific characteristics of a patient’s condition and enhance the effectiveness of therapies.

Monitoring Disease Progression: The biomarkers provide a reproducible method for monitoring disease progression, which is helpful in assessing the effectiveness of treatment and the need to change therapeutic approaches.

Advancing Clinical Research: In pharmaceutical research, the imaging biomarkers can act as objective endpoints in clinical trials, thus facilitating the evaluation of new treatments and accelerating the drug development process.